RTP Mobile Logo
Submitted by web@researchtop... on Thu, 06/16/2011 - 16:07

Proceedings from the 8th Annual Winter Lung Cancer Conference, 2011
Read All Issues PowerPoint Slides CE Information and Faculty Disclosures
CME Test
  • Select Presentations from the Meeting
    Please note that select presentations have been modified slightly from their original version
    because of issues related to slide permissions.

    Keynote  Lecture »
    Personalized Therapy in Lung Cancer: Ready for Prime Time?Thomas J Lynch Jr, MD     		 
       
    The New Biology of NSCLC »
    EGFR and K-ras mutations: Prognostic and predictive utilityThomas J Lynch Jr, MD
    Mechanisms of tumor resistance and irreversible EGFR tyrosine kinase inhibitors (TKIs)Vincent A Miller, MD
    Leveraging the EML4-ALK fusion gene in NSCLCGiuseppe Giaccone, MD, PhD
    Emerging multigene signatures for
    lung cancer risk stratification and
    treatment selection    John Heymach, MD, PhD
    Biomarkers of response or resistance to chemotherapy (eg, ERCC1, RRM1)Karen Kelly, MD

         		Current Controversies in the
    Management of Lung Cancer »
    Adjuvant systemic treatment of NSCLCRogerio C Lilenbaum, MD
    Multimodality treatment of locally advanced disease Everett E Vokes, MD
    Surgical treatment of N2 diseaseHarvey I Pass, MD
    Systemic treatment of small cell lung cancer (SCLC)Mark A Socinski, MD
    Consolidation radiation therapy after chemotherapy for SCLC Walter J Curran Jr, MD
    Comprehensive Management of
    Metastatic NSCLC »
    Chemobiologic treatment of advanced adenocarcinomaVincent A Miller, MD
    First-line therapy and switch or continuation maintenance in metastatic lung cancer Mark A Socinski, MD
    Chemobiologic treatment of advanced squamous carcinoma Karen Kelly, MD
    Management of lung cancer in the elderly — Therapeutic and palliative care considerationsRogerio C Lilenbaum, MD
    Key questions being answered in ongoing clinical trials in NSCLCGiuseppe Giaccone, MD, PhD
         		New Research Strategies,
    Agents and Ongoing Trials »
    Which are the most promising angiogenesis inhibitors in development (eg, triple angiokinase inhibitor, pan-VEGF inhibitor, VEGF Trap)?Ronald B Natale, MD
    Rationale for targeting c-MET in lung cancer: The BATTLE modelEdward S Kim, MD
    Techniques to stage the mediastinum — Is EBUS the standard?Harvey I Pass, MD
    Stereotactic radiosurgery — Current and future applications Walter J Curran Jr, MD
    New agents and targets in lung cancer (eg, novel cytotoxics, vaccines, small molecules)Edward S Kim, MD